PureTech to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, will present at the Jefferies Global Healthcare Conference on June 6, 2024. The event will feature a fireside chat with CEO Bharatt Chowrira and Co-founder Eric Elenko at 10:00am EDT / 3:00pm BST. A webcast of the presentation will be available on the PureTech Health investor website.

Positive

• PureTech's participation in the Jefferies Global Healthcare Conference enhances visibility among investors.
• The presentation by top executives, including the CEO and Co-founder, may provide important insights into the company’s future strategies and pipeline.

Negative

• No new financial data or clinical trial results were announced in this PR, offering immediate actionable information for investors.
• Relying on presentation events for visibility highlights potentially current market traction or breakthroughs.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6^th, 2024, at 10:00am EDT / 3:00pm BST. A webcast of the presentation will be available at https://investors.puretechhealth.com.

PureTech to Present at the Jefferies Global Healthcare Conference (Graphic: Business Wire)

About PureTech Health 
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements 
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the Jefferies Global Healthcare Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523522284/en/

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com

Source: PureTech Health plc

FAQ

When is PureTech Health presenting at the Jefferies Global Healthcare Conference?

PureTech Health is presenting on June 6, 2024, at 10:00am EDT / 3:00pm BST.

Who will represent PureTech Health at the Jefferies Global Healthcare Conference?

CEO Bharatt Chowrira and Co-founder Eric Elenko will represent PureTech Health.

Where can I watch PureTech Health's presentation at the Jefferies Global Healthcare Conference?

A webcast of the presentation will be available on the PureTech Health investor website.

What is the ticker symbol for PureTech Health?

The ticker symbol for PureTech Health is PRTC.